ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1857

Low Molecular Weight Heparin and Aspirin Combination Therapy Modulates Th1/Th2 Cell Imbalance in Pregnant Patients with Antiphospholipid Antibody-Associated Recurrent Pregnancy Loss

Meiying Wang1,2, Peng Zhang3, gengmin zhou1, jiyang lv1, chengshan guo4 and Qingwen Wang1, 1Rheumatology and Immunology, Peking University Shenzhen Hospital, shenzhen, China, 2Rheumtology, David Geffen school of Medicine at UCLA, Los Angeles, CA, 3SHENZHEN INSTITUTES OF ADVANCED TECHNOLOGY CHINESE ACADEMY OF SCIENCES, shenzhen, China, 4Rheumatology and Immunology, The people's Hospital of Bao’an District Shenzhen City., shenzhen, China

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Antiphospholipid antibodies, T cells and aspirin

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: 4M087 ACR Abstract: Reproductive Issues in Rheumatic Disorders (1852–1857)

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:

Type 1/type 2 T helper (Th1/Th2) cells and their cytokines are implicated in the pathogenesis of autoimmune diseases[1]; however, their roles in antiphospholipid antibody-associated recurrent pregnancy loss (APA-RPL) remain unclear[2,3]. Low molecular weight heparin (LMWH) and aspirin combination therapy is a first-line treatment for APA-RPL, but its mechanism remains unclear[4]. This study aimed to investigate the effect of combination therapy with LMWH and aspirin on Th1/Th2 cells and their cytokines in pregnant patients with APA-RPL.

Methods:

Pregnant patients with a history of APA-RPL (n=89) were enrolled in this study.After confirming a positive pregnancy test result, the patients were treated with LMWH and aspirin combination until 35–37 weeks of pregnancy or up to the time of miscarrige.Blood was drawn before starting and after stopping treatment. The therapeutic outcome was evaluated by using live-birth as an efficacy measurement.31 age matched healthy pregnant women who delivered in our hospital were used as a control group. ELISA was conducted to detect serum levels of the Th1 cytokines interleukin (IL)-2 and tumor necrosis factor alpha (TNF-α) and the Th2 cytokines IL-4 and IL-10. The percentages of CD4+-interferon gamma (INF-γ)+ and CD4+-IL-4+ cells among the CD4+ T cells in peripheral blood were assessed by flow cytometry, and the expression of T-bet and GATA 3 was determined by quantitative real-time PCR.

Results:

Of the 89 patients receiving LMWH-aspirin combination therapy, 72(80.9%) had a live birth and the remaining 17 had miscarriages. At 5-7 weeks of gestation in patients with APA-RPL, serum IL-2 (P=0.006) and TNF-α P<0.001) levels were significantly higher, while serum IL-4 (P=0.037) and IL-10 (P<0.001) levels were significantly lower compared to healthy pregnant control women( Figure 1).Similarly, the CD4+-INF-γ+-labeled Th1 cell subset was also significantly increased (P<0.001), while the CD4+-IL-4+-labeled Th2 cell subset was significantly reduced (P<0.001) in patients with APA-RPL( Figure 2). Furthermore, gene expression of T-bet was significantly elevated (P=0.003),while GATA3 mRNA expression was significantly reduced in patients with APA-RPL (P=0.002) ( Figure 3).This Th1-biased pattern was reversed in patients who had live birth while receiving the combination therapy. Patients with miscarriages continued to exhibit Th1-bias.

Conclusion:

Th1/Th2 cell frequencies and the protein and gene expression levels of their cytokines are perturbed in patients with APA-RPL, suggesting a possible role of Th1/Th2 imbalance in the pathogenesis of APA- RPL. Importantly, LMWH and aspirin combination therapy effectively reverse Th1 cell polarization for APA-RPL patients attaining live births, providing a new understanding of potential immunomodulatory mechanism of LMWH and aspirin combination therapy on APA-RPL.


Disclosure: M. Wang, None; P. Zhang, None; G. zhou, None; J. lv, None; C. guo, None; Q. Wang, None.

To cite this abstract in AMA style:

Wang M, Zhang P, zhou G, lv J, guo C, Wang Q. Low Molecular Weight Heparin and Aspirin Combination Therapy Modulates Th1/Th2 Cell Imbalance in Pregnant Patients with Antiphospholipid Antibody-Associated Recurrent Pregnancy Loss [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/low-molecular-weight-heparin-and-aspirin-combination-therapy-modulates-th1-th2-cell-imbalance-in-pregnant-patients-with-antip/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/low-molecular-weight-heparin-and-aspirin-combination-therapy-modulates-th1-th2-cell-imbalance-in-pregnant-patients-with-antip/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology